Home MS CureMS Treatments MS Review of Ocrelizumab + Q&A with Dr. Tim Vollmer

MS Review of Ocrelizumab + Q&A with Dr. Tim Vollmer

by admin


 
The FDA officially approved Ocrelizumab (brand name: Ocrevus) for use in multiple sclerosis treatment on March 28, 2017. In this live MS Q&A, Dr. Tim Vollmer answers many interesting questions on this new treatment option for MS patients.

Interesting Note:
A study of rituximab in MS with strong results, published in the New England Journal of Medicine in 2008, drove interest in B-cell depletion as a strategy to treat MS and has led to extensive off-label use of rituximab to treat primary and relapsing MS. Rituximab is a mouse protein, and is immunogenic in humans, and Genentech and its parent Roche decided to focus on the similar, but humanized mAb that they already had, Ocrelizumab, for MS instead.

You may also like